There is no licensed vaccine against any human parasitic disease and apicomplexan
parasites cause enormous human suffering; the malaria parasite alone kills approximately …

Background: Controlled human malaria infection (CHMI) studies are a vital tool to accelerate
vaccine and drug development. As CHMI trials are performed in a controlled environment …

Pronouncements have been made for more than 25 years that the development and
implementation of a highly effective malaria vaccine is imminent. In the case of pre …

Malaria is a major cause of morbidity and mortality. Immunity is acquired but is suboptimal,
being slow to develop and incomplete. An inadequate understanding of natural immunity …

Background Sterile protection in> 90% of volunteers against homologous Plasmodium
falciparum infection has been achieved only using the controlled human malaria infection …

After more than 50 years of intensive research and development, only one malaria vaccine
candidate,“RTS, S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy …

The development of protective vaccines against many difficult infectious pathogens will
necessitate the induction of effective antibody responses. Here we assess humoral immune …

Several species of Plasmodium cause a broad spectrum of human disease that range from
nausea and fever to severe anemia, cerebral malaria, and multiorgan failure. In malaria …

Malaria kills more than 600 000 people yearly, mainly children, and eradication is a global
priority. Malaria transmission-blocking vaccines are advancing in clinical trials, and …

The malaria parasite life cycle presents several targets for attack, but these different parts of
the life cycle are susceptible to different types of host immune response. For example, the …